<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568385</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-438/OCT-303</org_study_id>
    <secondary_id>U1111-1128-5905</secondary_id>
    <secondary_id>JapicCTI-121789</secondary_id>
    <nct_id>NCT01568385</nct_id>
  </id_info>
  <brief_title>A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in
      participants with a history of gastric or duodenal ulcer requiring long-term NSAID therapy
      will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Gastric Ulcer</condition>
  <condition>Duodenal Ulcer</condition>
  <arm_group>
    <arm_group_label>TAK-438 20 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-438</intervention_name>
    <arm_group_label>TAK-438 20 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants who, in the opinion of the principal investigator or subinvestigator, are
             capable of understanding the details of the study and complying with them.

          2. Prior to study commencement, participants who are capable of signing and dating the
             information/consent form.

          3. Participants with a chronic disease (rheumatoid arthritis, osteoarthritis, etc.) which
             requires continuous NSAID oral therapy for pain control during treatment period.

          4. Participants who meet either 1 or 2 below according to gastric or duodenal endoscopy:

               -  Ulcer scar (defined, in this study, as regenerative mucosa, convergence of
                  mucosal fold, gastric wall transformation, etc) has been confirmed during
                  endoscopy on the study drug initiation day (Visit 2).

               -  Ulcer (mucosal defects of 3 mm or larger with white moss) or ulcer scar has been
                  endoscopically confirmed before the study drug initiation day (Visit 2).

          5. Outpatient participants (inpatients for examinations are acceptable)

          6. Women with child-bearing potential must agree to routinely take appropriate
             contraceptive measures throughout treatment period, from giving consent to the study
             until 4 weeks after the final dose

        Exclusion Criteria:

          1. Participants who received treatment with another study drug (including approved drugs
             under post-marketing surveillance) within 84 days prior to commencement of screening

          2. Participants who have previously received TAK-438 in a clinical study or as a
             treatment

          3. Participants who are employees of institutions participating in this study and family
             members of such employees, participants in a dependent relationship with employees of
             institutions involved in conduct of the study (e.g., spouse, parent, child, sibling),
             and participants who are under duress in giving their consent

          4. Participants who have donated 400 mL or more of blood within 90 days prior to the
             commencement of screening

          5. Participants with a plan to change the type, dosage or administration of NSAID

          6. Participants with ulcer (mucosal defects of 3 mm or larger with white moss) or active
             hemorrhage confirmed during gastric or duodenal endoscopy on the study drug initiation
             day (Visit 2)

          7. Participants with small intestinal hemorrhage, large intestinal hemorrhage, or
             gastrointestinal hemorrhage of unknown cause

          8. Participants with a history of surgery or scheduled surgery influencing gastric acid
             secretion (resection of upper gastrointestinal tract or vagotomy etc)

          9. Participants with a history or complication of Zollinger-Ellison syndrome, or other
             gastric acid hypersecretion disorders

         10. Participants with a history or complication of aspirin asthma

         11. Participants who have a history of hypersensitivity or allergy to TAK-438 (including
             its excipients) or NSAIDs

         12. Participants with current use of illicit drug or a history of drug abuse. and/or
             alcohol dependence within one year prior to the commencement of screening

         13. Participants who require treatment with prohibited concomitant drugs or therapies (see
             7.3)

         14. Female participants who are pregnant or lactating; those who plan to become pregnant
             or donate ova during treatment period, from giving consent until 4 weeks after final
             dose

         15. Participants with serious central nervous system disorders, cardiovascular disease,
             pulmonary disease, hepatic disease, renal disease, metabolic disease, gastrointestinal
             disorders, urinary disorders, endocrine disease, or blood dyscrasia

         16. Participants who plan to undergo surgery requiring hospitalization or requires surgery
             during the study period.

         17. Participants with a history of a malignancy (or treatment thereof) within 5 years
             prior to the commencement of screening; however, participants with completely cured
             basal cell carcinoma of skin or carcinoma in situ of the cervix may be included in the
             study.

         18. Participants with acquired immune deficiency syndrome (AIDS; including HIV carriers)
             or hepatitis (including viral hepatitis carriers [HBs antigen or HCV antibody
             positive]); however, participants who are hepatitis C virus (HCV) antigen negative or
             HCV-RNA negative may be included in the study.

         19. Participants who meet either of the following laboratory test values at the beginning
             of screening (Visit 1)

               -  Serum creatinine value: higher than 2 mg/dL

               -  Alanine transaminase (ALT) or aspartate aminotransferase (AST): higher than 2.5 ×
                  the upper limit of normal

               -  Total bilirubin: higher than 2.0 × the upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Funabashi-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Noda-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annaka-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hakodate-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitahiroshima-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yubari-gun</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sanuki-shi</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yashiro-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sasebo-shi</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuchu-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric or duodenal ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
    <mesh_term>Duodenal Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

